Pfizer Corporation

Cadent Therapeutics, Inc.

Alkermes, Inc.

Rodin Therapeutics, Inc.

Pinteon Therapeutics Inc.

Martin R Jefson

John Adams Lowe, Iii

Fabian Dey

Gregg F Keaney

Janus Schreiber Larsen

Andreas Schoop

Thomas Amos Jacobsen

Karin Sandager Nielsen

Andreas Bergmann

Dipak Vasantrao Amrutkar

Kelly Foster

Junsuke Tone

Paul R McGuirk

Nathan Oliver Fuller

Satoshi Nishiyama

Hiroshi Maeda

John Michael McCall

Naoya Tsurushita

Shankar Kumar

Birgitte Langer Eriksen

Scott J Hecker

Russell Thomas

Katherine E Brighty

Kelvin S Holdom

James W McFarland

Charlotte Hougaard

Dorte Strøbæk

Kristin M Lundy

John C Ruddock

Magnus Gustafsson

Subramanian Sam Guhan

Michael K Ahlijanian

Keiji Kaneda

Burton Humphrey Jaynes

Adrian Schomburg

Nadia Lybøl Von Schoubye

Paul R Mc Guirk

Jeiji Kaneda

Junsukse Tone

Konstanze Konig Von Paumbshausen

Robert Gerald Linde, Iii

Jessica Klein

Ellen Lester McCormick

John A Iii Lowe

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Hetero-halo inhibitors of histone deacetylase

The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.

Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase

Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Inhibitors of histone deacetylase

This invention relates to compounds of the formula

Hygromycin derivatives

Derivatives of 16-membered ring 3-deoxy macrolide antibiotic derivatives of rosaramicin, repromicin, 5-mycaminosyltylonolide, desmycosin, lactenocin, O-demethyllactenocin, cirramycin A.sub.1, and 23-deoxymycaminosyltylonolide, which are useful against bacterial and mycoplasmic pathogens in animals.

Antibiotic macrolides

Derivatives of 16-membered ring antibiotic macrolides

The following 3-carboxaldehyde quinolines and naphthyridines have antibacterial activity ##STR1## wherein A, Y, R, and R.sub.2 are as defined herein. These compounds are particularly suitable for administration by injection. A specific example of such compound is 1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-y l]-4-oxo-1,4-dihydroquinoline-3-carboxaldehyde.

3-carboxaldehyde substituted quinolines and naphthyridines

Antibacterial compounds have the formula ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCl or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R.sup.2 is a bridged-diazabicycloalkyl group.

Substituted bridged diazabicycloalkyl quinolone carboxylic acids

N-demethylefrotomycin, a valuable new antibiotic substance, is produced by the microbial conversion of mocimycin using a novel, efrotomycin-producing, microbial species ATCC 53758.

N-demethylefrotomycin

Growing community of inventors

Stonington, CT, United States of America

Martin R Jefson